Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients

View through CrossRef
Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world, but other infections, toxic substances (e.g. alcohol, certain drugs), and auto-immune diseases can also cause hepatitis. To assess the treatment efficacy of sofosbuvir and velpatasvir to chronic hepatitis C virus-infected patients and to assess the treatment efficacy among the various subgroups of the treated patients. The primary endpoint will be to assess sustained virologic response at 12 weeks (sofosbuvir + velpatasvir) after the end of therapy. The objective of the study is that hepatitis C virus is a rare viral disease occurring in the society with prevalence rate to be around 0.5% to 1.5%. So this study helps to assess the safety and efficacy of sofosbuvir and velpatasvir in hepatitis C virus-infected patients. This study is a prospective study. The study was carried in Gandhi Hospital, Secunderabad, Telangana, India, which is a multispecialty hospital with a bed capacity of 1200. The study is conducted in the Gastroenterology and Hepatology department (both inpatients and OP patients). The present study shows that sofosbuvir and velpatasvir provides a significant effect by decreasing HCV RNA levels, decreasing the duration of therapy and fewer adverse events compared to other existing therapies. Low incidence of side effects in the present study established the safety profile of the drug in 6 months period. In this study, most adverse events noticed were headache and fatigue. Sofosbuvir and velpatasvir yield the most favourable future health economic outcomes, compared with other currently available regimens across a broad spectrum of patients, including those with different treatments. Further elucidation of the side effects, a more extended period of sofosbuvir and velpatasvir and, more number of patients need to be studied.
Title: To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients
Description:
Hepatitis is an inflammation of the liver.
The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer.
Hepatitis viruses are the most common cause of hepatitis in the world, but other infections, toxic substances (e.
g.
alcohol, certain drugs), and auto-immune diseases can also cause hepatitis.
To assess the treatment efficacy of sofosbuvir and velpatasvir to chronic hepatitis C virus-infected patients and to assess the treatment efficacy among the various subgroups of the treated patients.
The primary endpoint will be to assess sustained virologic response at 12 weeks (sofosbuvir + velpatasvir) after the end of therapy.
The objective of the study is that hepatitis C virus is a rare viral disease occurring in the society with prevalence rate to be around 0.
5% to 1.
5%.
So this study helps to assess the safety and efficacy of sofosbuvir and velpatasvir in hepatitis C virus-infected patients.
This study is a prospective study.
The study was carried in Gandhi Hospital, Secunderabad, Telangana, India, which is a multispecialty hospital with a bed capacity of 1200.
The study is conducted in the Gastroenterology and Hepatology department (both inpatients and OP patients).
The present study shows that sofosbuvir and velpatasvir provides a significant effect by decreasing HCV RNA levels, decreasing the duration of therapy and fewer adverse events compared to other existing therapies.
Low incidence of side effects in the present study established the safety profile of the drug in 6 months period.
In this study, most adverse events noticed were headache and fatigue.
Sofosbuvir and velpatasvir yield the most favourable future health economic outcomes, compared with other currently available regimens across a broad spectrum of patients, including those with different treatments.
Further elucidation of the side effects, a more extended period of sofosbuvir and velpatasvir and, more number of patients need to be studied.

Related Results

The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
This case report describes of a pharmacokinetic drug–drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, l...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
"TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"
"TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"
Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3
VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3
BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virolo...
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
We longitudinally studied 51 patients from two hemodialysis centers to determine the prevalence of hepatitis C virus infection in hemodialysis patients. Serum samples were tested f...

Back to Top